Analysts expect Nevro Corp. (NYSE:NVRO) to report $90.35 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Nevro’s earnings, with the highest sales estimate coming in at $91.20 million and the lowest estimate coming in at $89.00 million. Nevro posted sales of $70.53 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.1%. The company is expected to report its next quarterly earnings results on Thursday, February 22nd.

On average, analysts expect that Nevro will report full year sales of $90.35 million for the current year, with estimates ranging from $317.80 million to $319.90 million. For the next financial year, analysts anticipate that the company will report sales of $397.99 million per share, with estimates ranging from $374.70 million to $416.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Nevro.

Nevro (NYSE:NVRO) last announced its quarterly earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. The firm had revenue of $82.26 million during the quarter, compared to the consensus estimate of $80.50 million. Nevro had a negative return on equity of 17.27% and a negative net margin of 14.09%. The firm’s quarterly revenue was up 35.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.14) EPS.

NVRO has been the subject of several recent analyst reports. Northland Securities restated a “buy” rating and set a $96.00 target price on shares of Nevro in a research note on Tuesday, November 7th. Canaccord Genuity restated a “buy” rating and set a $120.00 target price on shares of Nevro in a research note on Sunday, October 8th. BidaskClub downgraded Nevro from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. TheStreet upgraded Nevro from a “d+” rating to a “c-” rating in a research note on Monday, November 6th. Finally, BMO Capital Markets restated a “buy” rating and set a $106.00 target price on shares of Nevro in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Nevro presently has an average rating of “Hold” and an average target price of $100.00.

In other news, Director Wilfred E. Jaeger sold 16,467 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $90.19, for a total transaction of $1,485,158.73. Following the transaction, the director now owns 1,518 shares of the company’s stock, valued at $136,908.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael F. Demane sold 25,000 shares of the stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $87.73, for a total transaction of $2,193,250.00. The disclosure for this sale can be found here. Insiders have sold 63,467 shares of company stock worth $5,576,679 in the last ninety days. Corporate insiders own 12.10% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new position in shares of Nevro during the third quarter worth about $636,000. Point72 Asset Management L.P. lifted its position in shares of Nevro by 35.4% during the third quarter. Point72 Asset Management L.P. now owns 542,952 shares of the medical equipment provider’s stock worth $49,343,000 after purchasing an additional 141,963 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Nevro by 27.9% during the third quarter. Jane Street Group LLC now owns 6,655 shares of the medical equipment provider’s stock worth $605,000 after purchasing an additional 1,450 shares during the last quarter. Royce & Associates LP lifted its position in shares of Nevro by 71.4% during the third quarter. Royce & Associates LP now owns 24,000 shares of the medical equipment provider’s stock worth $2,181,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Artisan Partners Limited Partnership lifted its position in shares of Nevro by 13.2% during the third quarter. Artisan Partners Limited Partnership now owns 433,649 shares of the medical equipment provider’s stock worth $39,410,000 after purchasing an additional 50,732 shares during the last quarter.

Shares of Nevro (NVRO) traded down $1.60 during trading on Friday, hitting $66.41. The stock had a trading volume of 571,187 shares, compared to its average volume of 479,595. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81. Nevro has a 12 month low of $65.40 and a 12 month high of $99.63.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/10/90-35-million-in-sales-expected-for-nevro-corp-nvro-this-quarter.html.

Nevro Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.